Your selection

Innovation / 02.10.2024
Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register

Berlin, 2 October 2024.

Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenburg (Berlin) District Court today. With the entry in the commercial register of Eckert & Ziegler SE, the spin-off of Pentixapharm AG became legally effective. All shares in Pentixapharm AG held by Eckert & Ziegler have thus been legally transferred from Eckert & Ziegler SE to Pentixapharm Holding AG.

In compensation, the shareholders of Eckert & Ziegler SE will receive Pentixapharm Holding AG shares at a ratio of 1:1. The number of Eckert & Ziegler shares held by each Eckert & Ziegler shareholder after the close of trading today, taking into account any outstanding stock market transactions, will determine their entitlement. All Pentixapharm Holding AG shares created as part of the spin-off are expected to be admitted to the Regulated Market of the Frankfurt Stock Exchange in the Prime Standard segment on 2 October 2024.

Initial trading of the Pentixapharm Holding AG shares is scheduled for 3 October 2024. On the same day, the listing of the Eckert & Ziegler SE shares ‘ex spin-off’ is planned. The deposit-side posting of the Pentixapharm Holding shares to the securities accounts of Eckert & Ziegler shareholders is expected to take place on 7 October 2024.

Further information on the IPO of Pentixapharm AG can be found here: www.pentixapharm.com

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Overview News

News Buch Berlin

Pentixapharm Holding AG: US National Cancer Institute Starts Advanced Clinical Trial with PentixaFor

The National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), two highly respected research organizations belonging to the US government's Natio...

more ...

Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply

Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today a...

more ...

Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register

Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenbu...

more ...

Events Buch Berlin

05.11.2024, 16:00
Die Zukunft der Hirnkrebstherapie: Fortschritte, Herausforderungen und Visionen

Vortrag in der Reihe: Neue Wege in der Biomedizin - Aktuelle Forschungsthemen des Campus Berlin-Buch

more ...

06.11.2024, 13:30
Einladung zur Vorlesung: "Rätselhafte Gehirne - Ursachen von Demenz bei Jung und Alt"

in der Reihe "Neue Wege in der Biomedizin: Aktuelle Forschungsthemen vom Campus Berlin-Buch"

more ...

11.11.2024, 09:00
Fachkraft für Molekularbiologie

Das 11-tägige Intensiv-Seminar vermittelt Grundlagenwissen zu den wichtigsten Labormethoden der modernen Molekularbiologie und vermittelt Einblicke in die klinische Forschung.

more ...

This website is supported by: